Skip to main content
Hesham Mohamed, MD, Pulmonology, Phoenix, AZ, St. Joseph's Hospital and Medical Center

HeshamEMohamedMD

Pulmonology Phoenix, AZ

Critical Care Medicine, Pleural Disease

Physician

Dr. Mohamed is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Mohamed's full profile

Already have an account?

Education & Training

  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 2013
  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 2011
  • Norwalk Hospital/Yale University
    Norwalk Hospital/Yale UniversityFellowship, Pulmonary Disease, 2011 - 2013
  • University of Nevada Reno School of Medicine
    University of Nevada Reno School of MedicineResidency, Internal Medicine, 2006 - 2009
  • University of Tripoli SOM
    University of Tripoli SOMClass of 1995

Certifications & Licensure

  • AZ State Medical License
    AZ State Medical License 2019 - 2024
  • WV State Medical License
    WV State Medical License 2015 - 2021
  • VA State Medical License
    VA State Medical License 2014 - 2020
  • NV State Medical License
    NV State Medical License 2009 - 2021
  • American Board of Internal Medicine Critical Care Medicine
  • American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

  • Most Compassionate Doctor American Registry

Publications & Presentations

PubMed

Abstracts/Posters

  • Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients wi...
    Hesham Mohamed, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with...
    Hesham Mohamed, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Hospital Affiliations